(Reuters) -Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) has announced that it has signed an access agreement with Pharmaceutical Company Gilead Sciences to procure lenacapavir, a ...

Gilead Sciences, Inc. (GILD) on Wednesday announced a strategic partnership agreement with the Global Fund to combat AIDS, ...

Only 17,000 Ugandans to benefit from $1.1m Global Fund support as officials warn of high demand for long-acting prevention ...

Gilead has partnered with Global Fund to supply lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP).

The Minister of Health, Dr. Sabin Nsanzimana, has cautioned that despite progress made in combating HIV/AIDS, the virus remains a serious threat and is increasingly re-emerging among young people. The ...

Severe cuts to international aid are disrupting lifesaving HIV services in vulnerable countries, with UNAIDS warning of millions of preventable infections and deaths if support isn’t restored.

The National Agency for the Control of AIDS (NACA) is set to host a high-level meeting to deliberate on sustainable ...

Gilead Sciences (NasdaqGS:GILD) recently announced a partnership with the Global Fund to supply lenacapavir for HIV ...

The Minister’s address was particularly notable for the announcement of a planned rollout of lenacapavir, a biannual ...

Nigeria must take bold steps to ensure that HIV prevention, treatment, and support remain accessible and resilient, ...